Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | BTK | Q06187 | 4/20 | 0.41 |
| ▸ | SRC | P12931 | 5/20 | 0.38 |
| ▸ | LYN | P07948 | 2/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501865 | 0.89 | PLA2G7 (0.41) | ALDH1A1BTKSRCLYNPLA2G7 | |
| SCHEMBL13376335 | 0.87 | ALDH1A1 (0.42) | ALDH1A1BTKSRCLYNPLA2G7 | |
| SCHEMBL502548 | 0.82 | SRC (0.47) | ALDH1A1SRCPLA2G7KITMEN1 | |
| SCHEMBL13376352 | 0.76 | PLA2G7 (0.42) | ALDH1A1BTKSRCPLA2G7GRM5 | |
| SCHEMBL502110 | 0.71 | SRC (0.51) | ALDH1A1SRCPLA2G7KITMEN1 | |
| SCHEMBL5061783 | 0.70 | BTK (0.49) | BTKSRCLYN | |
| SCHEMBL854684 | 0.69 | SRC (0.44) | ALDH1A1BTKSRCLYNGRM5 | |
| SCHEMBL5067126 | 0.69 | BTK (0.58) | BTKSRCLYNKIT | |
| SCHEMBL502525 | 0.68 | MAPK14 (0.53) | ALDH1A1SRCLCKKITNPSR1 | |
| SCHEMBL17119663 | 0.67 | BTK (0.48) | BTKSRCLYNTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-8106068-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2012-01-31 | — | — | US | disclosed |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2010-04-01 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| US-7678792-B2 | Compositions and methods for modulating c-kit and PDGFR receptors | IRM LLC (BM) | 2010-03-16 | — | — | US | disclosed |
| EP-2076513-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2009-07-08 | — | — | EP | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| WO-2008051757-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051757-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | IRM LLC (BM) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176846-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | ALDH1A1 4274/4885BTK 63/4885SRC 3/4885 |
| US-20100081656-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS | FYN, FLT3, SRC | ALDH1A1 4274/4885BTK 63/4885SRC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.